ClinConnect ClinConnect Logo
Search / Trial NCT06032195

Study of Organ Perfusion in Heart Transplantation in Children

Launched by DR. F. KÖHLER CHEMIE GMBH · Sep 8, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying two different solutions used to preserve hearts before they are transplanted into children. The main goal is to see if a new solution called Custodiol-N is safe to use compared to an older solution called Custodiol. Researchers want to know if using Custodiol-N can help ensure that the heart remains healthy and functional during the transplant for children who are waiting for their first heart transplant.

To join the trial, participants need to be under 18 years old and must be on the waiting list for a heart transplant. They should also be able to understand the study and give consent, or have a legal guardian who can do so on their behalf. If chosen for the study, participants will receive either a heart preserved with Custodiol-N or Custodiol, and their health will be monitored closely to ensure the safety of the new solution. It’s important to note that certain conditions, like severe other health issues or being part of another study recently, might prevent someone from participating.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age from birth to less than18 years
  • Recipients awaiting their first transplant
  • Ability of the patients and/ or their legal guardians to understand character and individual consequences of the clinical trial
  • written informed consent of the patients and/ or their legal guardians (must be available before enrolment in the study)
  • Patient listed on the waiting list for heart transplantation
  • Exclusion Criteria:
  • Patients who have participated within 30 days or are still participating in any other interventional studies
  • history of severe organic disease other than concerning the heart
  • history/demonstration of HIV antibodies or AIDS
  • multiorgan transplantation
  • machine-perfused organ
  • the explantation team is affiliated to another clinic than transplantation team
  • Failing Fontan patients
  • Patients who have been incarcerated or involuntarily institutionalized by court order or by the authorities
  • Pregnancy and lactation

About Dr. F. Köhler Chemie Gmbh

Dr. F. Köhler Chemie GmbH is a leading research-driven company specializing in the development and production of high-quality chemical solutions for various industries, including healthcare and pharmaceuticals. With a commitment to innovation and excellence, the company focuses on creating effective and safe products that meet rigorous regulatory standards. Leveraging advanced technologies and a strong emphasis on quality assurance, Dr. F. Köhler Chemie GmbH plays a vital role in supporting clinical trials and enhancing therapeutic outcomes, while prioritizing sustainability and customer satisfaction in all its endeavors.

Locations

Berlin, , Germany

Gießen, , Germany

München, , Germany

Patients applied

0 patients applied

Trial Officials

Christoph Knosalla, Prof. Dr.

Principal Investigator

German Heart Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported